Thesis supervisor: Lajos Géczi
Location of studies (in Hungarian): PTE ÁOK Pécs, Szigeti u. 12. Abbreviation of location of studies: ÁOK
Description of the research topic:
Traditionally, patients with metastatic disease are treated with combination chemotherapies or targeted agents. These cytotoxic agents have good response rates and achieve palliation; however, complete responses are rarely seen. The field of cancer immunology has made rapid advances in the past 20 years. The benefit of these agents is twofold, it enhances the body's own immune system to fight cancer, thus has a lower incidence of side effects compared to conventional therapy. Secondly a small but substantial number of patients with metastatic disease are cured by immunotherapy or achieve durable responses lasting for years. New therapeutic options have become available for the treatment of patients with locally advanced and metastatic urogenital carcinoma. The advent of T-cell checkpoint inhibitors, especially those directed at programmed death 1 (PD-1) and its ligand (PD-L1), has had a significant impact on the therapy of advanced urothelial cancer. Checkpoint inhibitors (anti-CTLA-4, -PD-1 and -PD-L1/2) and their combinations and targeted and immune-based therapy combination have improved outcome of advanced kidney cancer. Antibody-based targeted immunotherapy and dendritic-cell-based vaccination are among the therapies that are being evaluated to treat prostate cancer. Combination of radio- and chemotherapy with checkpoint inhibitors is ongoing. Information on how to personalize management and how to select and sequence existing therapies is lacking, as are predictive biomarkers.
Number of students who can be accepted: 1
Deadline for application: 2023-05-19
2024. IV. 17. ODT ülés Az ODT következő ülésére 2024. június 14-én, pénteken 10.00 órakor kerül sor a Semmelweis Egyetem Szenátusi termében (Bp. Üllői út 26. I. emelet).
Login
